眼科藥物市場 - 按治療類別（抗 VEGF、抗青光眼）、適應症（乾眼、過敏）、給藥途徑（局部）、類型（處方、非處方藥）、劑型（眼藥水、凝膠）、配銷通路, 全球預測，2024 - 2032

由於白內障、青光眼和老年黃斑部病變等眼部疾病和疾病發生率的增加，預計 2024 年至 2032 年眼科藥物市場的CAGR將達到 5.1%。世界衛生組織報告稱，白內障影響了約6,520萬人，其中80%以上的病例導致中度至重度視力喪失。這刺激了對眼科藥物的需求，因為這些病症通常需要藥物干預來管理或治療。

此外，該領域持續的研究和創新導致了新療法和藥物的引入，並提高了各種眼部疾病的治療效果。這些進步不僅滿足了現有的醫療需求，還提供了新的和改進的解決方案，從而吸引了醫療保健專業人員和患者。

眼科藥品產業根據劑型、治療類別、適應症、給藥途徑、產品、配銷通路和地區進行細分。

抗發炎藥物領域預計在預測期內大幅成長，因為它們有助於控制各種發炎性眼部疾病。發炎是許多眼部疾病的常見因素，例如葡萄膜炎和乾眼症。抗發炎藥，包括皮質類固醇和非類固醇抗發炎藥 (NSAID)，可透過減少發炎和緩解症狀來有效解決這些問題。

在近視盛行率不斷上升的推動下，近視細分市場將在 2024 年至 2032 年期間為市場帶來可觀的收入。對數位設備的日益依賴和螢幕時間的延長，尤其是在年輕人中，導致近視病例激增。隨著對管理和遏制近視的有效解決方案的需求不斷增加，製藥公司正在投資研發，從而推出專門滿足這一需求的新藥。

由於醫療保健意識不斷提高，亞太地區眼科藥物產業預計到 2032 年將顯著成長。眼部疾病的盛行率不斷增加，特別是在該地區的老年人口中。快速的城市化和生活方式的改變導致與眼睛相關的疾病激增。此外，醫療保健服務的可近性和對眼睛健康重要性的認知不斷提高，促使人們尋求早期診斷和治療，從而增加了對眼科藥物的需求。醫療保健基礎設施的進步和對預防保健的日益重視正在刺激區域市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：眼科藥品產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 眼部疾病盛行率增加
    • 與新藥開發相關的研究和開發不斷增加
    • 診斷和治療方式的技術進步
    • 提高對眼部疾病的認知
    • 老年人口不斷增加
    • 越來越關注開發聯合療法
  • 產業陷阱與挑戰
    • 流行藥物失去專利保護
    • 發展中國家缺乏健康保險
• 成長潛力分析
• 監管環境
  • 美國
  • 歐洲
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：眼科藥物市場規模與預測：依治療類別，2018-2032 年

• 主要動力向：依治療類別
• 抗VEGF劑
• 抗青光眼藥物
  • α激動劑
  • BETA受體阻斷劑
  • 前列腺素類似物
  • 聯合用藥
  • 其他抗青光眼藥物
• 抗發炎藥
  • 類固醇
  • 非類固醇抗發炎藥
• 抗感染藥
  • 抗菌藥物
  • 抗真菌藥物
  • 其他抗感染藥
• 抗過敏藥
• 其他治療類別

第 6 章：眼科藥物市場規模與預測：按適應症分類，2018-2032 年

• 主要動向：依指示
• 乾眼症
• 青光眼
• 感染/發炎
• 視網膜疾病
  • 濕AMD
  • 乾性AMD
  • 糖尿病性視網膜病變
  • 其他視網膜疾病
• 過敏
• 葡萄膜炎
• 近視
• 下垂症
• FECD
• 色素性視網膜炎
• 其他適應症

第 7 章：眼科藥物市場規模與預測：按給藥途徑，2018-2032 年

• 主要動向：按給藥途徑
• 專題
• 局部眼部（玻璃體內）
• 其他給藥途徑

第 8 章：眼科藥物市場規模及預測：依產品分類，2018-2032

• 主要動向：按產品
• 處方
• 場外交易

第 9 章：眼科藥物市場規模及預測：按劑型，2018-2032

• 主要動力方向：按劑型
• 眼藥水
• 膠囊和片劑
• 凝膠
• 藥膏
• 注射劑
• 奶油
• 其他劑型

第 10 章：眼科藥物市場規模及預測：依配銷通路，2018-2032

• 主要動向：按配銷通路
• 醫院藥房
• 零售藥局
• 網路藥局

第 11 章：眼科藥物市場規模及預測：按地區分類，2018-2032

• 主要動向：按地區
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 中東和非洲其他地區

第 12 章：公司簡介

• AbbVie, Inc.
• Alcon Vision LLC
• Bausch Health Companies, Inc.
• Bayer AG
• Coherus BioSciences
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer, Inc.
• Regeneron Pharmaceuticals, Inc.
• Santen, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

Ophthalmology Drugs Market is anticipated to record a CAGR of 5.1% from 2024 to 2032, driven by increasing incidences of eye disorders and diseases such as cataracts, glaucoma, and age-related macular degeneration. The World Health Organization report stated that cataracts affected approximately 65.2 million people and caused moderate to severe vision loss in over 80% of cases. This fuels the demand for ophthalmic drugs, as these conditions often require pharmaceutical interventions to manage or treat.

Additionally, ongoing research and innovation in the field lead to the introduction of novel therapies and medications, enhancing the effectiveness of treatments for various eye diseases. These advancements not only address existing medical needs but also offer new and improved solutions, thus attracting both healthcare professionals and patients.

Ophthalmology drugs industry is segmented based on dosage form, therapeutic class, indication, route of administration, product, distribution channel, and region.

Anti-inflammatory drugs segment is poised for substantial growth in the forecast period, as they help in managing various inflammatory eye conditions. Inflammation is a common factor in numerous eye disorders, such as uveitis and dry eye syndrome. Anti-inflammatory drugs, including corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), effectively address these conditions by reducing inflammation and alleviating symptoms.

Myopia segment will generate notable revenues for the market during 2024-2032, propelled by the escalating prevalence of nearsightedness. The increasing reliance on digital devices and prolonged screen time, especially among younger populations, is leading to surge in myopia cases. As the demand for effective solutions to manage and curb myopia rises, pharmaceutical companies are investing in R&D, leading to the introduction of novel drugs that cater specifically to this need.

Asia Pacific ophthalmology drugs industry is slated to witness a significant growth rate through 2032, attributed to rising healthcare awareness. There is an increasing prevalence of eye disorders, notably among the aging population in the region. Rapid urbanization and lifestyle changes contribute to a surge in eye-related conditions. Furthermore, the accessibility to healthcare services and heightened awareness about the importance of eye health are driving individuals to seek early diagnosis and treatment, thereby boosting the demand for ophthalmology drugs. The advancements in healthcare infrastructure and a growing emphasis on preventive care are stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 Data validation
• 1.5 Data Sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Global ophthalmology drugs industry 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Therapeutic class trends
  • 2.1.4 Indication trends
  • 2.1.5 Route of administration trends
  • 2.1.6 Product trends
  • 2.1.7 Dosage form trends
  • 2.1.8 Distribution channel trends

Chapter 3 Ophthalmology Drugs Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of eye disorders
    • 3.2.1.2 Rising research and development pertaining to the development of novel drugs
    • 3.2.1.3 Technological advances in diagnostic and treatment modalities
    • 3.2.1.4 Increase in awareness of eye disorders
    • 3.2.1.5 Growing geriatric population
    • 3.2.1.6 Increasing focus on developing combination therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Loss of patent protection for popular drugs
    • 3.2.2.2 Lack of health insurance in the developing countries
• 3.3 Growth potential analysis
  • 3.3.1 By therapeutic class
  • 3.3.2 By indication
  • 3.3.3 By route of administration
  • 3.3.4 By product
  • 3.3.5 By dosage form
  • 3.3.6 By distribution channel
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis, 2023
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard, 2023

Chapter 5 Ophthalmology Drugs Market Size and Forecast, By Therapeutic Class, 2018-2032 (USD Million)

• 5.1 Key trends, by therapeutic class
• 5.2 Anti-VEGF agents
• 5.3 Anti-glaucoma drugs
  • 5.3.1 Alpha agonist
  • 5.3.2 Beta blockers
  • 5.3.3 Prostaglandin analogs
  • 5.3.4 Combined medication
  • 5.3.5 Other anti-glaucoma drugs
• 5.4 Anti-inflammatory drugs
  • 5.4.1 Steroids
  • 5.4.2 NSAIDs
• 5.5 Anti-infective drugs
  • 5.5.1 Anti-bacterial drugs
  • 5.5.2 Anti-fungal drugs
  • 5.5.3 Other anti-infective drugs
• 5.6 Anti-allergy drugs
• 5.7 Other therapeutic categories

Chapter 6 Ophthalmology Drugs Market Size and Forecast, By Indication, 2018-2032 (USD Million)

• 6.1 Key trends, by indication
• 6.2 Dry eye
• 6.3 Glaucoma
• 6.4 Infection/inflammation
• 6.5 Retinal disorders
  • 6.5.1 Wet AMD
  • 6.5.2 Dry AMD
  • 6.5.3 Diabetic retinopathy
  • 6.5.4 Other retinal disorders
• 6.6 Allergy
• 6.7 Uveitis
• 6.8 Myopia
• 6.9 Ptosis
• 6.10 FECD
• 6.11 Retinitis pigmentosa
• 6.12 Other indications

Chapter 7 Ophthalmology Drugs Market Size and Forecast, By Route of Administration, 2018-2032 (USD Million)

• 7.1 Key trends, by route of administration
• 7.2 Topical
• 7.3 Local ocular (intravitreal)
• 7.4 Other routes of administration

Chapter 8 Ophthalmology Drugs Market Size and Forecast, By Product, 2018-2032 (USD Million)

• 8.1 Key trends, by product
• 8.2 Prescription
• 8.3 OTC

Chapter 9 Ophthalmology Drugs Market Size and Forecast, By Dosage Form, 2018-2032 (USD Million)

• 9.1 Key trends, by dosage form
• 9.2 Eye drops
• 9.3 Capsules and tablets
• 9.4 Gels
• 9.5 Ointments
• 9.6 Injectables
• 9.7 Cream
• 9.8 Other dosage forms

Chapter 10 Ophthalmology Drugs Market Size and Forecast, By Distribution Channel, 2018-2032 (USD Million)

• 10.1 Key trends, by distribution channel
• 10.2 Hospital pharmacies
• 10.3 Retail pharmacies
• 10.4 Online pharmacies

Chapter 11 Ophthalmology Drugs Market Size and Forecast, By Region, 2018-2032 (USD Million)

• 11.1 Key trends, by region
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
  • 11.4.6 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Midde East & Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 Rest of Middle East & Africa

Chapter 12 Company Profiles

• 12.1 AbbVie, Inc.
• 12.2 Alcon Vision LLC
• 12.3 Bausch Health Companies, Inc.
• 12.4 Bayer AG
• 12.5 Coherus BioSciences
• 12.6 F. Hoffmann-La Roche Ltd.
• 12.7 Novartis AG
• 12.8 Pfizer, Inc.
• 12.9 Regeneron Pharmaceuticals, Inc.
• 12.10 Santen, Inc.
• 12.11 Sun Pharmaceutical Industries Ltd.
• 12.12 Teva Pharmaceutical Industries Ltd.